Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized-controlled ELAN Trial.

Rohner, Roman; Kneihsl, Markus; Goeldlin, Martina B; Hakim, Arsany; Branca, Mattia; Abend, Stefanie; Valenzuela, Waldo Enrique; Fenzl, Sabine; Rezny-Kasprzak, Beata; Strbian, Daniel; Trelle, Sven; Paciaroni, Maurizio; Thomalla, Götz; Michel, Patrik; Nedeltchev, Krassen; Gattringer, Thomas; Sandset, Else C; Bonati, Leo; Aguiar de Sousa, Diana; Sylaja, P N; ... (2024). Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized-controlled ELAN Trial. Circulation, 150(1), pp. 19-29. American Heart Association 10.1161/CIRCULATIONAHA.124.069324

Text rohner-et-al-2024-early-versus-late-initiation-of-direct-oral-anticoagulants-after-ischemic-stroke-in-people-with.pdf - Accepted Version Restricted to registered users only until 17 November 2024. Available under License Publisher holds Copyright. Download (2MB)

BACKGROUND

Whether hemorrhagic transformation (HT) modifies the treatment effect of early versus late initiation of direct oral anticoagulation (DOAC) in people with ischemic stroke and atrial fibrillation is unknown.

METHODS

This is a post-hoc analysis of the ELAN trial. The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage (sICH), major extracranial bleeding, systemic embolism, or vascular death within 30 days. Secondary outcomes were the individual components, 30- and 90-day functional outcome. We estimated outcomes based on HT, subclassified as hemorrhagic infarction (HI) or parenchymal hemorrhage (PH) on pre-randomization imaging (core-lab rating) using adjusted risk differences (aRD) between treatment arms.

RESULTS

Overall, 247/1970 (12.5%) participants had HT (114 HI 1, 77 HI 2, 34 PH 1, 22 PH 2). For the primary outcome, the estimated aRD (early versus late) was -2.2% (-7.8 to 3.5%) in people with HT (HI: -4.7%, -10.8 to 1.4%; PH: 6.1%, -8.4 to 20.7%), and -0.9% (-2.6 to 0.8%) in people without. Numbers of sICH were identical in people with and without HT. With early treatment, the estimated aRD for poor 90-day functional outcome (mRS 3-6) was 11.4% (-0.9 to 23.7%) in participants with HT (HI: 7.2%, -6.6 to 21.0%; PH: 25.1%, 0.2 to 50.0%), and -2.6% (-7.1 to 1.8%) in people without HT.

CONCLUSIONS

We found no evidence of major treatment effect heterogeneity or safety concerns with early versus late DOAC initiation in people with and without HT. However, early DOAC initiation may worsen functional outcomes in people with PH.

Interest & Impact

Downloads

1 since deposited on 21 May 2024
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item